URGN Q1 2020 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$39M

Net Income

-$38M

EPS (Diluted)

$-1.79

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$36M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$167M

Total Liabilities

$16M

Stockholders' Equity

$150M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$22M	+100.0%
Operating Income	-$39M	-$22M	-71.9%
Net Income	-$38M	-$21M	-76.2%